A Pharmacokinetic Comparability Study of a Commercial Supply of Eptinezumab
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Acronyms ALD403-CLIN-014
- 23 Oct 2018 Results published in the Alder Biopharmaceuticals Media Release
- 23 Oct 2018 According to an Alder Biopharmaceuticals Media Release,Status changed from planning to completed.
- 20 Mar 2018 According to an Alder BioPharmaceuticals media release, this study is anticipated to complete in in the second half of 2018.